Literature DB >> 24604751

Prognostic paradox: brain damage around the glioblastoma resection cavity.

Takuya Furuta1, Mitsutoshi Nakada, Fumiaki Ueda, Takuya Watanabe, Yasuaki Arakawa, Ryo Higashi, Masaaki Hashimoto, Hisashi Nitta, Yutaka Hayashi, Jun-ichiro Hamada.   

Abstract

Hyperintense lesions around the resection cavity on magnetic resonance diffusion-weighted imaging (MR-DWI) frequently appear after brain tumor surgery due to the damage of surrounding brain. The putative connection between the lesion and the prognosis for patients with glioblastoma (GBM) was explored. This retrospective study reviewed consecutive sixty-one patients with newly diagnosed GBM. Postoperative MRI was performed within 2 weeks after the initial surgery. We classified the cases into two groups depending on whether DWI hyperintense lesions were observed or not [DWI(+) group and DWI(-) group]. Progression-free survival (PFS) and overall survival (OS) were compared between the two groups. Forty-two patients were identified. The various extents of hyperintense lesions around the resection cavity were observed in 28/42 (66.7%) cases. In the DWI(+) and DWI(-) groups, median PFS was 10.0 [95% confidence interval (CI) 8.4-11.5] and 6.7 (95% CI 4.9-8.5) months, respectively (p = 0.042), and median OS was 18.0 (95% CI 12.2-23.8) and 17.0 (95% CI 15.7-18.3) months, respectively (p = 0.254). On multivariate analysis, the presence of DWI hyperintense lesion was more likely to be an independent predictor for 6-month PFS (p = 0.019; HR, 0.038; 95% CI 0.002-0.582). Tumor recurrence appeared outside the former DWI hyperintense lesion. Hyperintense lesions surrounding the resected GBM on MR-DWI might be a favorable prognostic factor in patients with GBM.

Entities:  

Mesh:

Year:  2014        PMID: 24604751     DOI: 10.1007/s11060-014-1418-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

1.  Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age.

Authors:  Agi Oszvald; Erdem Güresir; Matthias Setzer; Hartmut Vatter; Christian Senft; Volker Seifert; Kea Franz
Journal:  J Neurosurg       Date:  2011-09-23       Impact factor: 5.115

2.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

3.  Technical pitfalls in a porcine brain retraction model. The impact of brain spatula on the retracted brain tissue in a porcine model: a feasibility study and its technical pitfalls.

Authors:  R Thiex; F J Hans; T Krings; B Sellhaus; J M Gilsbach
Journal:  Neuroradiology       Date:  2005-09-01       Impact factor: 2.804

4.  Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.

Authors:  Ramon F Barajas; Joanna J Phillips; Rupa Parvataneni; Annette Molinaro; Emma Essock-Burns; Gabriela Bourne; Andrew T Parsa; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

Review 5.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

6.  Clinical and radiographic features of peritumoral infarction following resection of glioblastoma.

Authors:  S Ulmer; T A Braga; F G Barker; M H Lev; R G Gonzalez; J W Henson
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

7.  Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury.

Authors:  Justin S Smith; Soonmee Cha; Mary Catherine Mayo; Michael W McDermott; Andrew T Parsa; Susan M Chang; William P Dillon; Mitchel S Berger
Journal:  J Neurosurg       Date:  2005-09       Impact factor: 5.115

8.  Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.

Authors:  Mary Lou Affronti; Christopher R Heery; James E Herndon; Jeremy N Rich; David A Reardon; Annick Desjardins; James J Vredenburgh; Allan H Friedman; Darell D Bigner; Henry S Friedman
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

9.  Spontaneous regression of intracerebral lymphoma.

Authors:  K L Weingarten; R D Zimmerman; N E Leeds
Journal:  Radiology       Date:  1983-12       Impact factor: 11.105

10.  Volumetric and MGMT parameters in glioblastoma patients: survival analysis.

Authors:  Georgios Iliadis; Vassiliki Kotoula; Athanasios Chatzisotiriou; Despina Televantou; Anastasia G Eleftheraki; Sofia Lambaki; Despina Misailidou; Panagiotis Selviaridis; George Fountzilas
Journal:  BMC Cancer       Date:  2012-01-03       Impact factor: 4.430

View more
  3 in total

Review 1.  Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria.

Authors:  Dewen Yang
Journal:  Neurooncol Pract       Date:  2015-07-12

2.  Epidermal Growth Factor (EGF) Augments the Invasive Potential of Human Glioblastoma Multiforme Cells via the Activation of Collaborative EGFR/ROS-Dependent Signaling.

Authors:  Maciej Pudełek; Kamila Król; Jessica Catapano; Tomasz Wróbel; Jarosław Czyż; Damian Ryszawy
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

Review 3.  The Pathophysiology of Post-Traumatic Glioma.

Authors:  Donata Simińska; Klaudyna Kojder; Dariusz Jeżewski; Ireneusz Kojder; Marta Skórka; Izabela Gutowska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2018-08-19       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.